Scientific Posters and Presentations

PARTIAL METHOD VALIDATION OF BIOMARKER ASSAYS TO DETERMINE ADRENOCORTICOTROPIC HORMONE (ACTH) CONCENTRATIONS IN RAT AND CANINE SERUM IN SUPPORT OF PRE-CLINICAL ENDOCRINOLOGY DRUG DEVELOPMENT

Michael Sonnenfelt presented Partial Method Validation of Biomarker Assays to Determine Adrenocorticotropic Hormone (ACTH) Concentrations in Rat and Canine Serum in Support of Pre-Clinical Endocrinology Drug Development in collaboration with Crinetics, at WRIB in June 2023.

EXPERIENCES OF CSF COLLECTION BY SERIAL SAMPLING OR LUMBAR PUNCTURE IN CLINICAL PHARMACOLOGY RESEARCH

Peter Dogterom, PhD presented Experiences of CSF collection by serial sampling or lumbar puncture in clinical pharmacology research at ASCPT 2023 in March 2023.

PHENOTYPIC CHARACTERIZATION OF hA53Ttg MICE AS PARKINSON’S DISEASE MODEL

Tina Loeffler, Marlene Mikusch, Richard Scheytt, Joerg Neddens, Roland Rabl, Magdalena Daurer, Livia Breznik, Sara Peinkiher, Stefanie Flunkert, Spyridon Sideromenos, Manuela Prokesch

NEUROINFLAMMATION IN THE EAE MODEL OF MULTIPLE SCLEROSIS

Joerg Neddens, Magdalena Daurer, Livia Breznik, Roland Rabl, Tina Loeffler, Sara Peinkiher, Stefanie Flunkert, Manuela Prokesch

ALRN-6924 INDUCES CELL CYCLE ARREST IN BONE MARROW STEM CELLS AND HAIR FOLLICLES WITH DOSE-DEPENDENT DEGREE AND DURATION OF EFFECTS AFTER A SINGLE INFUSION IN HEALTHY VOLUNTEERS

Sandra Henkelman¹, Christine Voors-Pette¹, Wytze Aalders¹, Aldert de Jong¹, Rick Brugman¹, Kevin Randall², Britta Will³, Ulrich Steidl³, Manuel Aivado², Vojislav Vukovic^{2, D. Allen Annis2}

Fmr1-KO MICE, A SUITABLE TOOL TO STUDY CORE AND SECONDARY SYMPTOMS OF AUTISM SPECTRUM DISORDERS

Shirin Sharghi^1,2, Stefanie Flunkert¹, Magdalena Daurer¹, Spyridon Sideromenos¹, Boris Philippe Chagnaud², Marcello Leopoldo³, Enza Lacivita³, Birgit Hutter-Paier¹, and Manuela Prokesch¹

Metallo Protein Quantitation by (LC-)ICP-MS

Abstract | Presentation

Eric van der Horst

Eric van der Horst presented Metallo Protein Quantitation by (LC-)ICP-MS on Tuesday, June 14, 2022

INCREASED RESPONSE OF 5XFAD MOUSE PRIMARY ADULT MICROGLIA TO DIFFERENT PRO-INFLAMMATORY STIMULI

Roland Rabl, Irene Schilcher, Tina Loeffler, Birgit Hutter-Paier, Manuela Prokesch

INJECTION OF PATIENT-DERIVED TAU SEEDS IN THE HIPPOCAMPUS OF HTAU MICE RESULTS IN TAU PHOSPHORYLATION AT SEVERAL RESIDUES

Roland Rabl, Irene Schilcher, Tina Loeffler, Martina Scharf, Magdalena Daurer, Joerg Neddens, Birgit Hutter-Paier, Manuela Prokesch

A NEW HUMAN Α-SYNUCLEIN A53T MOUSE MODEL EXHIBITING MULTIPLE PD-LIKE PHENOTYPES

Manuela Prokesch

Manuela Prokesch, PhD will be giving a presentation on Monday, May 16, 2022 at 14:00 (CEST)

BEHAVIORAL CHARACTERIZATION OF HOMOZYGOUS 6^NEO POMPE MICE

Spyridon Sideromenos, Agnes Molnar-Kasza, Livia Breznik, Roland Rabl, Stefanie Flunkert, Manuela Prokesch, Birgit Hutter-Paier

HUMAN ALZHEIMER’S DISEASE TAU SEEDS INCREASE TAU SEEDING AND UPTAKE IN DIFFERENT IN VITRO MODELS

Irene Schilcher, Tina Loeffler, Manuela Prokesch, Birgit Hutter-Paier

INCREASED RESPONSE OF PRIMARY ADULT MICROGLIA FROM 5xFAD MICE TO PRO-INFLAMMATORY STIMULI

Irene Schilcher, Tina Loeffler, Manuela Prokesch, Birgit Hutter-Paier

EDARAVONE REDUCES TDP-43 LEVEL BUT NOT STRESS GRANULE FORMATION IN SODIUM ARSENITE TREATED TDP-43 OVEREXPRESSING CELLS

Irene Schilcher, Tina Loeffler, Manuela Prokesch, Birgit Hutter-Paier

NEUROPROTECTIVE EFFECTS OF ASTAXANTHIN IN PRECLINICAL MODELS OF ALZHEIMER’S DISEASE

Babalola Joshua Adekunle^1,2, Löffler Tina², Schilcher Irene², Manuela Prokesch², Gerald Hoefler¹ and Birgit Hutter-Paier²

Oral Presentation: DISTRIBUTION OF TAU PHOSPHORYLATION AT SEVERAL RESIDUES AFTER INJECTION OF PATIENT-DERIVED SEEDS IN A TAU MOUSE MODEL

Irene Schilcher, Tina Löffler, Martina Scharf, Magdalena Daurer, Joerg Neddens, Manuela Prokesch, Birgit Hutter-Paier

Oral Presentation: BEHAVIORAL CHARACTERIZATION OF THE hA53Ttg OF PARKINSON’S DISEASE

Roland Rabl, Magdalena Daurer, Livia Breznik, Helena Aspernig, Stefanie Flunkert, Birgit Hutter-Paier, Manuela Prokesch

CHARACTERIZATION OF IN VIVO AND IN VITRO DRUG SCREENING MODELS FOR GAUCHER DISEASE BASED ON GBA-D409V-KI MICE

Tina Loeffler, Breznik Livia, Ewald Auer, Irene Schilcher, Birgit Hutter-Paier, Manuela Prokesch

Tina Loeffler, PhD will present the abstract during a moderated poster session on Thursday, February 10, 2022 from 3:00-5:00 PM (PST)

BEHAVIORAL CHARACTERIZATION OF HOMOZYGOUS 6^NEO MICE AS MODEL OF POMPE DISEASE

Livia Breznik, Spyridon Sideromenos, Agnes Molnar-Kasza, Roland Rabl, Stefanie Flunkert, Manuela Prokesch, Birgit Hutter-Paier

Livia Breznik, MSc will present the abstract during a moderated poster session on Thursday, February 10, 2022 from 3:00-5:00 PM (PST)

THE DEVELOPMENT OF A HYBRIDIZATION ECLIA ASSAY FOR THE DETERMINATION OF THE PAYLOAD OF A OLIGONUCLEOTIDE-ANTIBODY CONJUGATE

Niels Nijstad, PhD

Niels Nijstad, PhD will be making a presentation on Day 1 – Wednesday 24th Nov. 2021 14:40 - 15:00.

BEHAVIOURAL CHARACTERIZATION OF THE FMR1 KNOCK-OUT MOUSE MODEL OF AUTISM SPECTRUM DISORDER (ASD)

Shirin Sharghi^1,2, Magdalena Daurer¹, Stefanie Flunkert¹, Boris Philippe Chagnaud², Marcello Leopoldo³, Enza Lacivita³ and Birgit Hutter-Paier¹

ASTAXANTHIN ENHANCES LRP1-MODULATED INSULIN SENSITIVITY AND AMYLOID BETA CLEARANCE IN AN IN VITRO BLOOD-BRAIN BARRIER MODEL

Joshua Adekunle Babalola^1,2,3, Magdalena Lang², Meekha George², Anika Stracke², Jelena Tadic⁴, Frank Madeo⁴, Achim Lass⁴, Gerd Leitinger⁵, Birgit Hutter-Paier³, Gerald Hoefler¹ and Ute Panzenboeck²

BTBR T+ Itpr3tf/J MICE, A SUITABLE ANIMAL MODEL TO STUDY ANXIETY AND REPETITIVE BEHAVIORS IN AUTISM SPECTRUM DISORDER

Shirin Sharghi^1,2, Magdalena Daurer¹, Stefanie Flunkert¹, Boris Philippe Chagnaud², Marcello Leopoldo³, Enza Lacivita³ and Birgit Hutter-Paier¹

A53T-MUTATED HUMAN Α-SYNUCLEIN IS INVOLVED IN BLOOD GLUCOSE REGULATION OF WESTERN TYPE DIET-FED PARKINSON’S DISEASE MICE

Magdalena Daurer^1,2, Roland Rabl¹, Heinrich Roemer², Birgit Hutter-Paier¹

IN VITRO AND IN VIVO MODELING OF MUTATED A53T ALPHA-SYNUCLEIN PATHOLOGY

Tina Loeffler, Roland Rabl, Irene Schilcher, Magdalena Daurer, Stefanie Flunkert, Birgit Hutter-Paier

REPURPOSING OF THE ANTI-ASTHMATIC DRUG MONTELUKAST FOR THE TREATMENT OF PARKINSON’S DISEASE

Katharina Strempfl^1,2,3, Michael S. Unger^2,3, Ludwig Aigner^2,3, Jörg Neddens¹, Stefanie Flunkert¹, Birgit Hutter-Paier¹

COMPARISON OF TWO DIFFERENT IN VITRO MODELS OF NEUROINFLAMMATION: CYTOKINE RELEASE AND INFLAMMASOME ACTIVATION IN ORGANOTYPIC SLICES AND BV2 CELLS

Irene Schilcher, Tina Loeffler, Stefanie Flunkert, Birgit Hutter-Paier

TREATMENT OF APP_SL TRANSGENIC MICE WITH AN ALDH2 ACTIVATOR AS A PROMISING TREATMENT OPTION FOR ALZHEIMER’S DISEASE

Barbara Hinteregger^1,2, Stefanie Flunkert¹, Tobias Madl², Joerg Neddens¹, Wenjin Yang³ and Birgit Hutter-Paier¹

CHARACTERIZATION OF 4L/PS-NA MICE FOR CYTOKINE ACTIVITY AND NEURODEGENERATION

Tina Loeffler, Ewald Auer, Irene Schilcher, Birgit Hutter-Paier

Tina Loeffler, Ph. D. will be taking part in a Live Q&A on Thursday, February 11 from 2:30-3:30pm EST

EVALUATION OF CD45 POSITIVE CELLS IN THE BRAIN AND LIVER OF NPC1-/- MICE

Magdalena Daurer, Ewald Auer, Joerg Neddens, Birgit Hutter-Paier

Magdalena Dauerer, Ph.D. will be taking part in a Live Q&A on Thursday, February 11 from 2:30-3:30pm EST

DEVELOPMENT AND VALIDATION OF A TRASTUZUMAB/PERTUZUMAB HYBRID LC-MS ASSAY FOR CLINICAL DEVELOPMENT

Fabrizia Fusetti, Ph.D.

Fabrizia Fusetti, Ph.D. will be making a presentation on Day 2, 18 November 2020 14:30-14:50.

STRATEGIES FOR THE PREVENTION OF NON-SPECIFIC BINDING IN THE QUANTITATIVE DETERMINATION OF DRUGS IN CEREBROSPINAL FLUID

Martijn Hilhorst, Robbert Edens, Bert Ottjes, Benjamin Steenge and Ben van Baar

DEVELOPMENT OF A HYBRID METHOD FOR SIMULTANEOUS QUANTIFICATION OF TWO NEAR IDENTICAL PROTEINS IN PLASMA

Chris Williams, Thomas Fokkinga, Francesco Bonardi, Fabrizia Fusetti and Martijn Hilhorst

BIOANALYTICAL MONITORING OF GENE THERAPY TRIALS: METHODOLOGIES FOR PK PROFILING OF OLIGONUCLEOTIDES

Fabrizia Fusetti¹, Zamas Lam², Monique Putman¹, Susan Zondlo², Brad Yuska², Lakshmi Ramanathan², Tim Snow²

NEUROFILAMNENT-LIGHT CHAIN IN MURINE MODELS OF NEURODEGENERATIVE AND RARE DISEASES

Irene Schilcher, Tina Loeffler, Stefanie Flunkert, Birgit Hutter-Paier

INFLAMMASOME ACTIVATION AND REDUCED sTREM2 RELEASE IN LPS STIMULATED ORGANOTYPIC BRAIN SLICES

Irene Schilcher, Tina Loeffler, Stefanie Flunkert, Birgit Hutter-Paier

CORRELATION OF Aβ-pE(3) AND ptau IN HUMAN AND MOUSE BRAIN

Magdalena Temmel¹, Joerg Neddens¹, Stefanie Flunkert¹, Lauren Walker², Johannes Attems², Birgit Hutter-Paier¹

Neuroinflammation in Mouse Models of Two Different Lysosomal Diseases

Vera Niederkofler, Ewald Auer, Victoria Schiffer, Magdalena Temmel, Joerg Neddens, Birgit Hutter-Paier

APPLICATION OF LC-HRMS IN PHARMACOKINETICS AND METABOLISM OF OLIGONUCLEOTIDES

Helen Shen, Ph.D.

Poster Time: Tuesday, Jan. 21st at 1:00-1:35 p.m.

Helen Shen, Ph.D., will be giving a presentation on Tuesday, January 21st at 1:00-1:35 p.m. at the Sheraton Bucks County Langhorne about the topic of the poster.

BIOANALYTICAL MONITORING OF GENE THERAPY TRIALS: METHODOLOGIES FOR PK-PD ASSESSMENT AND PATIENT ELIGIBILITY

Fabrizia Fusetti

Fabrizia Fusetti will be making a presentation during the plenary session in the 02 Auditorium (Innovate) on Friday, November 22nd at 12:10 pm.

DETERMINATION OF MOXIFLOXACIN IN HUMAN PLASMA AND FECES BY LC-MS/MS

Martijn Hilhorst¹, Violaine Augustin², and Robbert Edens¹

A STUDY TO DETERMINE THE POTENTIAL EFFECTS OF DISSOLUTION RATE AND FOOD ON THE PHARMACOKINETICS OF TRIENTINE 2HCL FOLLOWING SINGLE ORAL ADMINISTRATIONS IN HEALTHY SUBJECTS

Peter Dogterom¹, Mireille Gerrits², Khalid Abd-Elaziz¹, Daphne van Scheppingen³, Carlot Kruse³

A DRUG-DRUG INTERACTION STUDY TO STUDY THE EFFECTS OF MULTIPLE DOSES OF THE CYP3A4 MODULATORS ITRACRONAZOLE AND RIFAMPIN ON THE SINGLE DOSE PHARMACOKINETICS OF VATIQUINONE

ChauHwei Fu, Peter Dogterom, Donald Burkindine, Thomas Chou, Christie Elliott, Martin Thoolen

A Drug-Drug Interaction Study to Study the Effects of Multiple Doses of the CYP3A4 Modulators Itraconazole and Rifampin on the Single Dose Pharmacokinetics of Vatiquinone

SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ACT017, AN ANTI-PLATELET GPVI (GLYCOPROTEIN VI) FAB IN HEALTHY VOLUNTEERS

Peter Dogterom, Christine Voors-Pette, Thomas Chou, Laurien Jullien, Kristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard

INFLUENCE OF RIFAMPIN-MEDIATED OATP1B1/1B3 INHIBITION ON THE PHARMACOKINETICS OF CLAZOSENTAN

Peter Dogterom, Pierre-Eric Juif, Christine Voors-Pette, Mike Ufer, Jasper Dingemanse

A DRUG-DRUG INTERACTION STUDY: THE EFFECTS OF MULTIPLE DOSES OF THE CYP3A4 MODULATORS ITRACONAZOLE AND RIFAMPIN ON THE SINGLE DOSE PHARMACOKINETICS OF VATIQUINONE

Peter Dogterom, ChauHwei Fu, Thomas Chou, Thomas Wade, Christie Elliott, Martin Thoolen

CHARACTERIZATION OF RELEVANT MOUSE MODELS FOR NEW BIOMARKERS

Vera Niederkofler, Tina Loeffler, Stefanie Flunkert, Agnes Kasza, Ewald Auer, Birgit Hutter-Paier

BEHAVIORAL CHARACTERIZATION OF LOW COPY SOD1 G93A TRANSGENIC MICE

Stefanie Flunkert, Roland Rabl, Agnes Kasza, Vera Niederkofler, Ewald Auer, Birgit Hutter-Paier

RELEVANCE OF CHOICE OF BRAIN REGION AND TIME POINT OF ANALYSIS AFTER MPTP LESIONING IN WILDTYPE MICE

Jan Kehr^1,3, Victoria Schiffer², Shimako Yoshitake¹, Tina Loeffler², Vera Niederkofler², Stefanie Flunkert², Ewald Auer², Takashi Yoshitake³, Birgit Hutter-Paier²

CHARACTERIZATION OF 4L/PS-NA MICE FOR DIFFERENT BIOMARKERS TO MODEL GAUCHER DISEASE

Stefanie Flunkert¹, Staffan Schmidt², Tina Loeffler¹, Vera Niederkofler¹, Joerg Neddens¹, Maria Posch¹, Ewald Auer¹, Jan Kehr², Birgit Hutter-Paier¹

P1-112: PROGRESSIVE INCREASE OF ALZHEIMER’S DISEASE PATHOLOGY IN 5XFAD TRANSGENIC MICE

Tina Loeffler, Magdalena Temmel, Jörg Neddens, Irene Schilcher, Birgit Hutter-Paier.

P3-113: UNTANGLING ALZHEIMER´S DISEASE HALLMARKS IN SENSORY SYSTEMS OF RODENT MODELS

Joerg Neddens¹, Magdalena Temmel¹, Meritxell Aguilo Garcia^1,2, Tina Loeffler¹, Irati Aiestaran Zelaia¹, Vera Niederkofler¹, Stefanie Flunkert¹, Birgit Hutter-Paier¹

P4-061: TAU PHOSPHORYLATION PROFILE OF HTAU TRANSGENIC MICE

Joerg Neddens, Tina Loeffler, Magdalena Temmel, Irene Schilcher, David Amschl, Birgit Hutter-Paier

P4-062: IN VITRO MODELS TO STUDY TAU AGGREGATION, PHOSPHORYLATION AND UPTAKE

Tina Loeffler, Irene Schilcher, Stefanie Flunkert, Birgit Hutter-Paier

BEHAVIORAL CHARACTERIZATION OF HOMOZYGOUS BACHD RATS

Tina Loeffler¹, Stephan Kurat¹, Adam Horvath¹, Stefanie Flunkert¹, Hoa Huu Phuc Nguyen^2,3, Robert Wronski¹, Birgit Hutter-Paier¹

TAU PHOSPHORYLATION PROFILE OF HTAU TRANSGENIC MICE

Joerg Neddens, Tina Loeffler, Magdalena Temmel, Irene Schilcher, David Amschl, Birgit Hutter-Paier

CONSTRUCTION OF A TAU SEED-INJECTION MODEL USING HTAU MICE

Shigeru Akasofu¹, Jane Gartlon², Malcolm Roberts², Ezat Sajedi³, Rohan de Silva³, Tina Loeffler⁴, Stephan Duller⁴, Birgit Hutter-Paier⁴

INNERVATION OF SKIN SAMPLES OF Α-SYNUCLEIN TRANSGENIC MICE: LINE 61, D-LINE, A53T

Joerg Neddens, Estibaliz Etxebarria, Victoria Krivitsch, Birgit Hutter-Paier

UNTANGLING ALZHEIMER´S DISEASE HALLMARKS IN SENSORY SYSTEMS OF RODENT MODELS

Magdalena Temmel¹, Meritxell Aguilo Garcia^1,2, Tina Loeffler¹, Joerg Neddens¹, Irati Aiestaran Zelaia¹, Vera Niederkofler¹, Stefanie Flunkert¹ and Birgit Hutter-Paier¹

PROGRESSIVE INCREASE OF ALZHEIMER’S DISEASE PATHOLOGY IN 5XFAD TRANSGENIC MICE

Magdalena Temmel, Tina Loeffler, Joerg Neddens, Irene Schilcher, Birgit Hutter-Paier

SAFETY, TOLERABILITY AND PHARMACODYNAMIC RESULTS OF A FIRST IN HUMAN STUDY WITH THE NEW ANTIPLATELET AGENT ACT017 FOR THE TREATMENT OF THE ACUTE PHASE OS ISCHEMIC STROKE

Christine Voors-Pette¹, Peter Dogterom¹, Laurie Jullien², Martine Jandrot-Perrus³, and Gilles Avenard²

CHARACTERIZATION OF 4L/PS-NA MICE FOR ENZYME ACTIVITY

Vera Niederkofler¹, Ewald Auer¹, Victoria Schiffer¹, Tina Loeffler¹, Joerg Neddens¹,Staffan Schmidt², Jan Kehr², Birgit Hutter-Paier¹

BEHAVIORAL AND HISTOLOGICAL HALLMARKS OF A MUCOPOLYSACCHARIDOSIS TYPE IIIA MOUSE MODEL

Vera Niederkofler¹, Ewald Auer¹, David Amschl¹, Joerg Neddens¹, Elisabet Ohlin Sjöström², Susanne Gustavsson², Birgit Hutter-Paier¹

CBE TREATMENT OF Α-SYNUCLEIN OVEREXPRESSING AND WILDTYPE MICE MODELS GAUCHER DISEASE PATHOLOGY

Vera Niederkofler, Ewald Auer, David Amschl, Joerg Neddens, Birgit Hutter-Paier

CONSTRUCTION OF A TAU-SEED INJECTION MODEL USING hTau MICE

Birgit Hutter-Paier¹, Shigeru Akasofu², Jane Gartlon³, Malcolm Roberts³, Ezat Sajedi⁴, Rohan de Silva⁴, Tina Löffler¹, Stephan Duller¹.

PATHOLOGICAL HALLMARKS OF A GENETIC AND AN INDUCED GAUCHER DISEASE MOUSE MODEL

Joerg Neddens, Estibaliz Santiago-Mugica, Stefanie Flunkert, Vera Niederkofler, Roland Rabl, David Amschl, Maria Posch, Ewald Auer, Birgit Hutter-Paier.

LEARNING AND MEMORY DEFICITS OF TWO TRANSGENIC ALZHEIMER’S DISEASE MOUSE MODELS IN THE BARNES MAZE TEST

Ewald Auer, Stephan Kurat, Roland Rabl, Iera Hernandez, Stefanie Flunkert, Vera Niederkofler, Birgit Hutter-Paier.

METABOLIC CHARACTERISTICS OF PRIMARY NEURON CULTURES FROM BACHD RATS COMPARED TO INDUCED LESION MODELS

Stefanie Flunkert¹, Tina Loeffler¹, Benedikt Fabry¹, Hoa Huu Phuc Nguyen^2,3, Robert Wronski¹, Birgit Hutter-Paier¹

BEHAVIORAL CHARACTERIZATION OF HOMOZYGOUS BACHD RATS

Stephan Kurat¹, Adam Horvath¹, Stefanie Flunkert¹, Hoa Huu Phuc Nguyen^2,3, Robert Wronski¹, Birgit Hutter-Paier¹

INTEGRATIVE CHARACTERIZATION OF A RODENT ALZHEIMER’S DISEASE MODEL

Barbara Hinteregger^1,2, Tobias Madl², Joerg Neddens¹, Robert Wronski¹, Birgit Hutter-Paier¹

THE BARNES MAZE TEST – A DRY LAND BEHAVIORAL TEST TO ANALYZE ALZHEIMER’S DISEASE MOUSE MODELS FOR SPATIAL LEARNING DEFICITS

Roland Rab^l, Stephan Kurat, Iera Hernandez, Estibaliz Santiago, Stefanie Flunkert, Birgit Hutter-Paier

FOCALLY INDUCED TAU PATHOLOGY IN APPSL MICE CLOSER MIMICS ALZHEIMER’S DISEASE SPATIO‐TEMPORAL PATHOLOG

Meritxell Aguiló^1,2, Ewald Auer¹, Tina Loeffler¹, Balázs Dobrovich¹, Joerg Neddens¹, Stefanie Flunkert¹, Robert Zimmermann², Birgit Hutter‐Paier¹

SERUM VEGF LEVELS ARE ASSOCIATED WITH COGNITION AND FUNCTIONING IN AD: INFLUENCE OF THE TREATMENT WITH CEREBROLYSIN AND DONEPEZIL

A. Alvarez^1,2, I. Alvarez¹, O. Iglesias², M. Aleixandre³, C. Linares4, J. Figueroa^1,5

UNTANGLING ALZHEIMER’S DISEASE HALLMARKS IN SENSORY SYSTEMS OF RODENT MODELS

Roland Rabl, Meritxell Aguiló, Tina Löffler, Jörg Neddens, Ainara Lopez, Vera Niederkofler, Stefanie Flunkert and Birgit Hutter-Paier

NUTRIOSE^®, A SOLUBLE FIBRE WITH DEMONSTRATED BENEFITS FOR BLOOD GLUCOSE MANAGEMENT IN HUMANS

Guérin-Deremaux L¹, Hobden MR², Thabuis C¹, Vazhappilly R¹, Kalman D³, Kennedy OB²

A FAST, ROBUST, AND GENERIC IA-LC-MS/MS METHOD FOR QUANTIFICATION OF MONOCLONAL ANTIBODY THERAPEUTICS: OPTIMIZING IMMUNOAFFINITY CAPTURE, PROTEOLYTIC DIGEST, AND LC CONDITIONS

Shuyu Hou, Feng-Ming James Chang, Kevin Pei, Mark Kai Leung Ho, Tyler Prusisz, Susan Zondlo, and John Kolman

DEVELOPMENT OF A UPLC-MS/MS METHOD FOR THE DETERMINATION OF NORETHINDRONE FROM HUMAN PLASMA

Lan Li, Jinlan Dong, Tracey Paxson, Lin Zhang, Yuan-Shek Chen

AN LC-MS/MS METHOD FOR THE EVALUATION OF FF-10502-01 INCORPORATION INTO WHOLE BLOOD CELLULAR DNA AS A PHARMACODYNAMIC MARKER

Yuzhu Xue¹, Tiffany Chen¹, Brittney Offenbacker¹, MingLai Cheng¹, Takayuki Yamada², Timothy Madden3, Yuan-Shek Chen¹, Jamie Zhao¹, Susan Carr Zondlo¹

DEVELOPMENT OF A UPLC-MS/MS METHOD FOR THE SIMULTANEOUS DETERMINATION OF FIVE MONOMETHYL AURISTATIN E (MMAE) METABOLITES FROM HUMAN PLASMA

Lan Li¹, Tracey Paxson¹, Yuan-Shek Chen¹, Martin Paton², Mark Qian²

DEVELOPMENT OF A UPLC-MS/MS METHOD FOR THE DETERMINATION OF MLN9708 AND ITS ENANTIOMER FROM HUMAN PLASMA

Lan Li¹, Yuan-Shek Chen¹, Martin Paton², Mark Qian²

VALIDATION OF A POLYMERASE CHAIN REACTION (RT-qPCR) TO QUANTIFY A CODON-OPTIMIZED HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MRNA (CO-hCFTR)

MingLai Cheng¹, Katherine Domingue¹, Lihong Gao², Jonathan Abysalh², Teresa White², Susan Zondlo¹, and John L. Kolman₁ 

A STUDY TO EVALUATE THE PHARMACOKINETICS AND TASTE PROFILE OF A PROTOTYPE ORALLY DISINTEGRATING TABLET FORMULATION FOR MK-0663

Peter Dogterom¹, Khalid Abd Elaziz¹, Ruben de Jong¹, Susan J. Lee² and Paul Fackler²